Journal Mobile Options
Table of Contents
Vol. 156, No. 2, 2011
Issue release date: September 2011
Int Arch Allergy Immunol 2011;156:179–186

Azithromycin Inhibits IL-5 Production of T Helper Type 2 Cells from Asthmatic Children

Lin S.-J. · Lee W.-J. · Liang Y.-W. · Yan D.-C. · Cheng P.-J. · Kuo M.-L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Childhood asthma is a type 2 helper T (Th2) cell-driven inflammatory airway disease characterized by recurrent episodes of airway obstruction. Azithromycin (AZM), a macrolide antibiotic exhibiting anti-inflammatory activity aside from its antibacterial effect, may prove beneficial for asthmatic children. This study aimed to determine the effect of AZM on Th2 cells from atopic asthmatic children and non-atopic controls. Methods: CD4+ cells were isolated from peripheral blood mononuclear cells of 9 patients with asthma and 9 non-atopic individuals. Cells were activated as Th0 and differentiated into Th2 cells. The effect of AZM on activated CD4+ cells was evaluated with respective cell proliferation and cytokine production. Results: Th0 and Th2 CD4+ T cells from atopic asthmatic children produced greater interleukin (IL)-5 (Th2 cytokine) but lower interferon (IFN)-γ (Th1 cytokine) compared to the non-atopic controls, respectively. AZM inhibited IL-5 production of Th0 and Th2 cells from atopic asthmatics in a dose-dependent fashion, without significantly affecting their IL-13 and IFN-γ production. A similar effect was observed in non-atopic controls except that AZM did inhibit IFN-γ production of their Th0 cells. AZM at a higher dose decreased cell viability by inhibiting CD4+ T cell proliferation and enhanced their apoptosis, an effect similarly observed in Th0 and Th2 cells, and did not differ between asthmatic children and controls. Conclusion: Our finding that AZM preferentially downregulates IL-5 production suggests its therapeutic potentials in controlling childhood asthma.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720–1745.
  2. Nakajima H, Takatsu K: Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007;142:265–273.
  3. Yang KD: Childhood asthma: aspects of global environment, genetics and management. Chang Gung Med J 2000;23:641–661.
  4. Bjermer L: Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol 2007;120:1269–1275.
  5. Lovett CJ, Whitehead BF, Gibson PG: Eosinophilic airway inflammation and the prognosis of childhood asthma. Clin Exp Allergy 2007;37:1594–1601.
  6. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112:S1–S40.
  7. Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157:S1–S53.
  8. Skoner DP, Maspero J, Banerji DP: Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008;121:e1–e14.
  9. Shinkai M, Rubin BK: Macrolides and airway inflammation in children. Paediatr Respir Rev 2005;6:227–235.
  10. Amsden GW: Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10–21.
  11. Mitsuyama T, Hidaka K, Furuno T, Hara N: Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997;114:111–115.
  12. Tamaoki J: The effects of macrolides on inflammatory cells. Chest 2004;125:41S–51S.
  13. Shinkai M, Mo H, Rubin BK: Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008;17:393–405.

    External Resources

  14. Gotfried MH: Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004;125:52S–60S.
  15. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, Papamichalopoulos A: Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004;23:714–717.
  16. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG: Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148–155.
  17. Amsden GW: Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 2001;18:S11–S15.
  18. Ekici A, Ekici M, Erdemoglu AK: Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 2002;39:181–185.
  19. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, Boner AL: Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007;28:194–198.
  20. Mizunoe S, Kadota J, Tokimatsu I, Kishi K, Nagai H, Nasu M: Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol 2004;4:1201–1207.
  21. Williams AC, Galley HF, Watt AM, Webster NR: Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 2005;56:502–506.
  22. Ito T, Ito N, Hashizume H, Takigawa M: Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells. J Dermatol Sci 2009;54:185–191.
  23. Lin CC, Liaw SF, Wu KM, Lin CH: Effect of erythromycin on bronchial hyperreactivity and inflammation in ovalbumin-sensitized brown Norway rats. Respir Physiol Neurobiol 2008;161:267–272.
  24. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wuthrich B: A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813–824.
  25. Liu P, Allaudeen H, Chandra R, Phillips K, Jungnik A, Breen JD, Sharma A: Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007;51:103–109.
  26. Wilms EB, Touw DJ, Heijerman HGM: Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Therapeut Drug Monitor 2006;28:219–225.
  27. Asano K, Kamakazu K, Hisamitsu T, Suzaki H: Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro. Int Immunopharmacol 2001;1:1913–1921.
  28. Ishimatsu Y, Kadota J, Iwashita T, Nagata T, Ishii H, Shikuwa C, Kaida H, Mukae H, Kohno S: Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrob Agents 2004;24:247–253.
  29. Jun YT, Kim HJ, Song MJ, Lim JH, Lee DG, Han KJ, Choi SM, Yoo JH, Shin WS, Choi JH: In vitro effects of ciprofloxacin and roxithromycin on apoptosis of Jurkat T lymphocytes. Antimicrob Agents Chemother 2003;47:1161–1164.
  30. Aoshiba K, Nagai A, Konno K: Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995;39:872–877.
  31. Huang JL, Chen LC, Yeh KW, Lin SJ, Hsieh KH, Kuo ML: Th1 and Th2 cytokine production among asthmatic children after immunotherapy. J Asthma 2003;40:273–279.
  32. Hirose H, Matsuse H, Tsuchida T, Fukahori S, Fukushima C, Mizuta Y, Kohno S: Cytokine production from peripheral blood mononuclear cells of mite allergen-sensitized atopic adults stimulated with respiratory syncytial virus and mite allergen. Int Arch Allergy Immunol 2008;146:149–155.
  33. Minty A, Asselin S, Bensussan A, Shire D, Vita N, Vyakarnam A, Wijdenes J, Ferrara P, Caput D: The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur Cytokine Network 1997;8:203–213.
  34. Jiang H, Harris MB, Rothman P: IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063–1070.
  35. Georas SN, Guo J, De Fanis U, Casolaro V: T-helper cell type-2 regulation in allergic disease. Eur Respir J 2005;26:1119–1137.
  36. Eum SY, Maghni K, Tolloczko B, Eidelman DH, Martin JG: IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2005;288:576–584.
  37. Lee YC, Lee KH, Lee HB, Rhee YK: Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. J Asthma 2001;38:665–671.
  38. Beigelman A, Gunsten S, Milols CL, Vidavsky I, Cannon CL, Brody SL, Walter MJ: Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 2009;36:498–506.

    External Resources

  39. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH: Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000;118:1826–1827.
  40. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, Nakagawa H, Hasegawa H, Nakabayashi M, Ishizaki Y: Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594–598.
  41. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB; TELICAST Investigators: The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589–1600.
  42. Tagaya E, Tamaoki J, Kondo M, Nagai A: Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002;122:213–218.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50